Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin's lymphoma: phase I safety and efficacy. (2nd June 2022)

• Record Type: Journal Article
• Authors: Yoshimitsu, Makoto; Ando, Kiyoshi; Ishida, Takashi; Yoshida, Shinichiro; Choi, Ilseung; Hidaka, Michihiro; Takamatsu, Yasushi; Gillings, Mireille; Lee, Gloria T; Onogi, Hiroshi; Tobinai, Kensei
• Is Part Of: Japanese journal of clinical oncology. Volume 52:Number 9(2022)
• Page Start: 1014
• Page End: 1020
• Publication Date: 2022-06-02
• Subjects: ATL -- NHL -- tucidinostat -- HDAC inhibitor -- HBI-8000; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyac086
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Objective: HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) with direct anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunomodulation. It has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma. Methods: This multicenter, prospective phase I dose-escalation trial evaluating the safety of twice weekly HBI-8000 was conducted in Japan. Eligible patients had non-Hodgkin's lymphoma and no available standard therapy. The primary endpoint was maximum tolerated dose; secondary endpoints included anti-tumor activity, safety and pharmacokinetics. Results: Fourteen patients were enrolled in the study. Twelve patients were assessed for dose-limiting toxicity: six patients in the 30 mg BIW cohort had no dose-limiting toxicitys; two of six patients in the 40 mg BIW cohort had asymptomatic dose-limiting toxicitys. Treatment was well tolerated; adverse events were predominantly mild to moderate hematologic toxicities and were managed with dose modification and supportive care. Thirteen patients were included in the efficacy analysis. Objective response was seen in five of seven patients in the 40 mg BIW cohort; three partial responders had adult T-cell leukemia-lymphoma. In the 30 mg BIW cohort, three of six patients had stable disease after the first cycle. Conclusions: Treatment with HBI-8000 30 and 40 mg BIW were well-tolerated and safe, with hematological toxicities as expected from other studies of histone deacetylase inhibitor. The maximum tolerated dose and recommended dosage for phase II studies of HBI-8000 is 40 mg BIW. Preliminary efficacy results are encouraging. Abstract : A phase I study demonstrated tolerability and safety of HBI-8000 in Japanese patients with non-Hodgkin's lymphoma. The maximum tolerated dose is 40 mg BIW. Preliminary efficacy results are encouraging.